Is Section 3(d) of India’s Patents Act a workable provision? The long-term effect.
31 October 2021
On April 1, 2013, the Supreme Court of India delivered a landmark decision in the Novartis Glivec case on the interpretation of Section 3(d) of the Indian Patents Act.
To continue reading this article, please Login or Register to be a subscriber
